Long-term results of tailored D2 lymph node dissection after R0 surgery for gastric cancer

被引:5
作者
Catarci M. [1 ,2 ]
Montemurro L.A. [1 ]
Ghinassi S. [1 ]
Di Cintio A. [1 ]
Leone L. [1 ]
Cosentino L.M. [1 ]
Viarengo M.A. [1 ]
Grassi G.B. [1 ]
机构
[1] Department of Surgery, San Filippo Neri Hospital, Rome
[2] Center for Clinical Evidence, San Filippo Neri Hospital, Rome
关键词
Lymph node ratio; Prognostic factors; Stomach neoplasms; Surgery;
D O I
10.1007/s13304-011-0065-8
中图分类号
学科分类号
摘要
Implementation of extended lymph node dissection for gastric cancer in western non-specialized centers through tailoring its extent upon disease stage and patient comorbidities was suggested as a wise policy to reduce morbidity and mortality rates, albeit with a potential for undertreatment in elderly and/or comorbid patients. Current definition of R0 resection for gastric cancer lacks consideration of treatment-related variables such as extended lymph node dissection. Few studies to date have tried to fill this gap in such a clinical context. A retrospective evaluation of factors influencing long-term results after R0 surgery was done in a prospective series of a non-specialized western surgical unit during the implementation of D2 lymphadenectomy. Univariate and multivariate analysis of 22 variables were performed on a prospective database of 233 consecutive R0 resections performed by ten different surgeons in 10 years. Endpoint was disease-free survival calculated at 5 and at 10 years. Disease-free survival rates were independently influenced by age, American Society of Anesthesiologists (ASA) status and lymph node ratio. Subset analysis of the status at censor stratified for age and ASA status failed to identify any significant difference in disease recurrence rates. Lymph node ratio was the only treatment-related independent prognostic factor for longterm results after R0 surgery for gastric cancer in the setting of a non-specialized western unit, where the extent of lymph node dissection needs to be tailored on the presence of comorbidities (ASA status). © 2011 Springer-Verlag.
引用
收藏
页码:83 / 90
页数:7
相关论文
共 47 条
[1]  
Cuschieri A., Weeden S., Fielding J., Bancewicz J., Craven J., Joypaul V., Sydes M., Fayers P., Patient survival after D<sub>1</sub> and D<sub>2</sub> resections for gastric cancer: Long-term results of the MRC randomized surgical trial, British Journal of Cancer, 79, 9-10, pp. 1522-1530, (1999)
[2]  
Bonenkamp J.J., Hermans J., Sasako M., Van De Velde C.J.H., Extended lymph-node dissection for gastric cancer, New England Journal of Medicine, 340, 12, pp. 908-914, (1999)
[3]  
McCulloch P., Niita M.E., Kazi H., Gama-Rodrigues J.J., Gastrectomy with extended lymphadenectomy for primary treatment of gastric cancer, British Journal of Surgery, 92, 1, pp. 5-13, (2005)
[4]  
Elias D., Reflections and proposals for the worldwide standardization of lymphadenectomy for gastric carcinoma, Journal of Surgical Oncology, 71, 2, pp. 120-122, (1999)
[5]  
Sano T., Tailoring treatments for curable gastric cancer, British Journal of Surgery, 94, 3, pp. 263-264, (2007)
[6]  
Lamb P., Sivashanmugam T., White M., Irving M., Wayman J., Raimes S., Gastric cancer surgery - A balance of risk and radically, Annals of the Royal College of Surgeons of England, 90, 3, pp. 235-242, (2008)
[7]  
Catarci M., Ghinassi S., Di Cintio A., Et al., Implementation and early results of extended lymph node dissection for gastric cancer in a non-specialized western center, Open Surg Oncol J, 2, pp. 4-10, (2010)
[8]  
Sobin L.H., Wittekind C.H., TNM Classification of Malignant Tumors, (2002)
[9]  
Heberer G., Teichmann R.K., Kramling H.J., Gunther B., Results of gastric resection for carcinoma of the stomach: The European experience, World J Surg, 12, pp. 374-381, (1988)
[10]  
Allum W.H., Powell D.J., McConkey C.C., Fielding J.W.L., Gastric cancer: A 25-year review, British Journal of Surgery, 76, 6, pp. 535-540, (1989)